Crinetics Pharmaceuticals, Inc. (CRNX) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 80.1% | -9534.5% | -8585.2% |
| 2024 | 100.0% | -32613.5% | -28720.7% |
| 2023 | 100.0% | -5547.2% | -5345.9% |
| 2022 | 100.0% | -3544.1% | -3460.4% |
| 2021 | 100.0% | -9990.9% | -9985.3% |
Download Data
Export CRNX earnings history in CSV or JSON format
Free sign-in required to download data
Crinetics Pharmaceuticals, Inc. (CRNX) Earnings Overview
As of March 2, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) reported trailing twelve-month net income of -$465M, reflecting -0.3% year-over-year growth. The company earned $-4.95 per diluted share over the past four quarters, with a net profit margin of -85.9%.
Looking at the long-term picture, CRNX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2016.
Crinetics Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), CRNX has room to improve margins relative to the peer group. Compare CRNX vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$465M | -55.9% | -$517M | $-4.95 | -8585.2% | -9534.5% |
| 2024 | -$298M | -39.1% | -$339M | $-3.69 | -28720.7% | -32613.5% |
| 2023 | -$215M | -30.9% | -$223M | $-3.69 | -5345.9% | -5547.2% |
| 2022 | -$164M | -52.3% | -$168M | $-3.15 | -3460.4% | -3544.1% |
| 2021 | -$108M | -45.8% | -$108M | $-2.80 | -9985.3% | -9990.9% |
| 2020 | -$74M | -49.0% | -$75M | $-2.42 | -103960.6% | -105567.6% |
| 2019 | -$50M | -82.7% | -$54M | $-2.05 | -4152.1% | -4512.3% |
| 2018 | -$27M | -196.1% | -$29M | $-2.23 | -1116.8% | -1182.5% |
| 2017 | -$9M | -52.1% | -$9M | $-0.66 | -447.8% | -446.3% |
| 2016 | -$6M | - | -$6M | $-0.43 | -1021.9% | -1026.1% |
See CRNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRNX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CRNX vs AGIO
See how CRNX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CRNX growing earnings?
CRNX EPS of $-4.95 reflects slowing growth at -0.3%, below the 5-year CAGR of N/A. TTM net income is $-465M. Expansion rate has moderated.
What are CRNX's profit margins?
Crinetics Pharmaceuticals, Inc. net margin is -85.9%, with operating margin at -95.3%. Below-average margins reflect competitive or cost pressures.
How consistent are CRNX's earnings?
CRNX earnings data spans 2016-2025. The current earnings trend is -0.3% YoY. Historical data enables comparison across business cycles.